Last reviewed · How we verify
Paclitaxel protein bound
Paclitaxel protein-bound stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division in cancer cells.
Paclitaxel protein-bound stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.
At a glance
| Generic name | Paclitaxel protein bound |
|---|---|
| Sponsor | Barts & The London NHS Trust |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin (microtubule) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Paclitaxel is a taxane that binds to microtubule proteins and prevents their disassembly, causing cell cycle arrest in the G2/M phase and triggering apoptosis. The protein-bound formulation (nab-paclitaxel) uses albumin nanoparticles to deliver paclitaxel, improving solubility and potentially enhancing tumor uptake compared to conventional formulations.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Pancreatic cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Thrombocytopenia
- Arthralgia/myalgia
- Fatigue
- Nausea/vomiting
- Alopecia
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
- CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel protein bound CI brief — competitive landscape report
- Paclitaxel protein bound updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI